Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 5/2021

23.08.2021 | Review

KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future

verfasst von: Byung Hyun Byun, Myoung Hyoun Kim, Yeon-Hee Han, Hwan-Jeong Jeong

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

This year, the Korean Society of Nuclear Medicine (KSNM) is celebrating its 60th anniversary. Treatment, as well as diagnosis, has played a very important role in the development of nuclear medicine. Since I-131 was used for thyroid therapy in 1959, other radionuclide therapy is still being used, and attempts to use new radionuclide are increasing. In this review, we briefly summarize and introduce the therapies such as radioimmunotherapy, transarterial radioembolization, radionuclide therapy for neuroendocrine tumors, peptide receptor radionuclide therapy, control of metastatic bone pain, radiation synovectomy, radionuclide brachytherapy, alpha particle therapy, and boron neutron capture therapy, which has been being attempted so far in the field of nuclear medicine.
Literatur
1.
Zurück zum Zitat Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, et al. Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma(NHL). Asia Pac J Clin Oncol. 2011;7:136–45.CrossRef Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, et al. Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma(NHL). Asia Pac J Clin Oncol. 2011;7:136–45.CrossRef
2.
Zurück zum Zitat Lee I, Byun BH, Lim I, Kim BI, Choi CW, Kim KM, et al. Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. Ann Nucl Med. 2019;33:881–90.CrossRef Lee I, Byun BH, Lim I, Kim BI, Choi CW, Kim KM, et al. Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. Ann Nucl Med. 2019;33:881–90.CrossRef
3.
Zurück zum Zitat Kang HJ, Lee SS, Byun BH, Kim KM, Lim I, Choi CW, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2013;71:945–53.CrossRef Kang HJ, Lee SS, Byun BH, Kim KM, Lim I, Choi CW, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2013;71:945–53.CrossRef
4.
Zurück zum Zitat Shin DY, Byun BH, Kim KM, Kang JH, Lim I, Kim BI, et al. Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2016;78:825–31.CrossRef Shin DY, Byun BH, Kim KM, Kang JH, Lim I, Kim BI, et al. Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2016;78:825–31.CrossRef
5.
Zurück zum Zitat Seelam SR, Banka VK, Lee YS, Jeong JM. 188Re Labeled liver therapeutic drugs for hepatic carcinoma (HCC). J Radiopharm Mol Probes. 2019;5:26–35. Seelam SR, Banka VK, Lee YS, Jeong JM. 188Re Labeled liver therapeutic drugs for hepatic carcinoma (HCC). J Radiopharm Mol Probes. 2019;5:26–35.
6.
Zurück zum Zitat Lee JT, Kim EK, Won JY, Lee DY, Lee JD, Yoo NC, et al. Experimental and clinical studies on the intraarterial injection of holmium-166 chitosan complex in the treatment of hepatocellular carcinoma. J Korean Radiol Soc. 2001;44:441–51.CrossRef Lee JT, Kim EK, Won JY, Lee DY, Lee JD, Yoo NC, et al. Experimental and clinical studies on the intraarterial injection of holmium-166 chitosan complex in the treatment of hepatocellular carcinoma. J Korean Radiol Soc. 2001;44:441–51.CrossRef
7.
Zurück zum Zitat Sohn JH, Choi HJ, Lee JT, Lee JD, Kim JH, Yoon YM, et al. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Oncology. 2009;76:1–9.CrossRef Sohn JH, Choi HJ, Lee JT, Lee JD, Kim JH, Yoon YM, et al. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Oncology. 2009;76:1–9.CrossRef
8.
Zurück zum Zitat Kim JK, Han KH, Lee JT, Paik YH, Ahn SH, Lee JD, et al. Long-term clinical outcome of phase iib clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res. 2006;12:543–8.CrossRef Kim JK, Han KH, Lee JT, Paik YH, Ahn SH, Lee JD, et al. Long-term clinical outcome of phase iib clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res. 2006;12:543–8.CrossRef
9.
Zurück zum Zitat Kim DY, Park BJ, Kim YH, Han KH, Cho SB, Cho KR, et al. Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol. 2015;38:495–501.CrossRef Kim DY, Park BJ, Kim YH, Han KH, Cho SB, Cho KR, et al. Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol. 2015;38:495–501.CrossRef
10.
Zurück zum Zitat Shehta A, Lee JM, Suh KS, Kim HC, Hong SK, Cho JH, et al. Bridging and downstaging role of trans-arterial radio-embolization for expected small remnant volume before liver resection for hepatocellular carcinoma Ann Hepatobiliary. Pancreat Surg. 2020;24:421–30. Shehta A, Lee JM, Suh KS, Kim HC, Hong SK, Cho JH, et al. Bridging and downstaging role of trans-arterial radio-embolization for expected small remnant volume before liver resection for hepatocellular carcinoma Ann Hepatobiliary. Pancreat Surg. 2020;24:421–30.
11.
Zurück zum Zitat Cho YY, Lee MJ, Kim HC, Chung JW, Kim YH, Gwak GY. Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS One. 2016;11:e0154986.CrossRef Cho YY, Lee MJ, Kim HC, Chung JW, Kim YH, Gwak GY. Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS One. 2016;11:e0154986.CrossRef
12.
Zurück zum Zitat Rhee SH, Kim SG, Cho JH, Park JK, Eo JS, Park SY, et al. Semi-quantitative analysis of post-transarterial radioembolization 90Y microsphere positron emission tomography combined with computed tomography (PET/CT) images in advanced liver malignancy: comparison with (99m)Tc macroaggregated albumin (MAA) single photon emission computed tomography (SPECT). Nucl Med Mol Imaging. 2016;50:63–9.CrossRef Rhee SH, Kim SG, Cho JH, Park JK, Eo JS, Park SY, et al. Semi-quantitative analysis of post-transarterial radioembolization 90Y microsphere positron emission tomography combined with computed tomography (PET/CT) images in advanced liver malignancy: comparison with (99m)Tc macroaggregated albumin (MAA) single photon emission computed tomography (SPECT). Nucl Med Mol Imaging. 2016;50:63–9.CrossRef
13.
Zurück zum Zitat Kim YC, Kim YH, Um SH, Seo YS, Park EK, Oh SY, et al. Usefulness of bremsstrahlung images after intra-arterial Y-90 resin microphere radioembolization for hepatic tumors. Nucl Med Mol Imaging. 2011;45:59–67.CrossRef Kim YC, Kim YH, Um SH, Seo YS, Park EK, Oh SY, et al. Usefulness of bremsstrahlung images after intra-arterial Y-90 resin microphere radioembolization for hepatic tumors. Nucl Med Mol Imaging. 2011;45:59–67.CrossRef
14.
Zurück zum Zitat Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging. 2012;46:102–10.CrossRef Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging. 2012;46:102–10.CrossRef
15.
Zurück zum Zitat Yoon JK, Ryoo BY, Lee CH, Jeong SH, Cheon YK, Choi CW, et al. 131I-MIBG therapy in malignant pheochromocytoma and medullary thyroid carcinoma. Korean J Nucl Med. 1995;29:319–27. Yoon JK, Ryoo BY, Lee CH, Jeong SH, Cheon YK, Choi CW, et al. 131I-MIBG therapy in malignant pheochromocytoma and medullary thyroid carcinoma. Korean J Nucl Med. 1995;29:319–27.
16.
Zurück zum Zitat Kim KH, Kim SM, Seo YD. A Discrepancy between 131I-Metaiodobenzylguanidine (131I-MIBG) scintigraphy and 18F-FDG PET/CT after 131I-MIBG therapy in a patient with recurred malignant pheochromocytoma. Nucl Med Mol Imaging. 2009;43:582–7. Kim KH, Kim SM, Seo YD. A Discrepancy between 131I-Metaiodobenzylguanidine (131I-MIBG) scintigraphy and 18F-FDG PET/CT after 131I-MIBG therapy in a patient with recurred malignant pheochromocytoma. Nucl Med Mol Imaging. 2009;43:582–7.
17.
Zurück zum Zitat Suh JK, Koh KN, Min SY, Kim YS, Kim H, Im HJ, et al. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with 131I-MIBG therapy for high-risk neuroblastoma. Pediatr Transplant. 2020;24:e13658.CrossRef Suh JK, Koh KN, Min SY, Kim YS, Kim H, Im HJ, et al. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with 131I-MIBG therapy for high-risk neuroblastoma. Pediatr Transplant. 2020;24:e13658.CrossRef
18.
Zurück zum Zitat Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, et al. Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017;10:108.CrossRef Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, et al. Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017;10:108.CrossRef
19.
Zurück zum Zitat Lee JW, Kang ES, Sung KW, Yi E, Lee SH, Yoo KH, et al. Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. Pediatr Blood Cancer. 2017;64(6). https://doi.org/10.1002/pbc.26399. Lee JW, Kang ES, Sung KW, Yi E, Lee SH, Yoo KH, et al. Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. Pediatr Blood Cancer. 2017;64(6). https://​doi.​org/​10.​1002/​pbc.​26399.
20.
Zurück zum Zitat Chung HW, Park JW, Lee EJ, Jung KH, Paik JY, Lee KH. 131I-MIBG targeting of neuroblastoma cells is acutely enhanced by KCl stimulation through the calcium/calmodulin-dependent kinase pathway. Cancer Biother Radiopharm. 2013;28:488–93.CrossRef Chung HW, Park JW, Lee EJ, Jung KH, Paik JY, Lee KH. 131I-MIBG targeting of neuroblastoma cells is acutely enhanced by KCl stimulation through the calcium/calmodulin-dependent kinase pathway. Cancer Biother Radiopharm. 2013;28:488–93.CrossRef
21.
Zurück zum Zitat Lee H, Suh M, Choi H, Ha S, Paeng JC, Cheon GJ, et al. A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy. EJNMMI Res. 2020;10:42.CrossRef Lee H, Suh M, Choi H, Ha S, Paeng JC, Cheon GJ, et al. A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy. EJNMMI Res. 2020;10:42.CrossRef
24.
Zurück zum Zitat Kim MH, Kim SG, Kim DW. Dual-labeled prostate-specific membrane antigen (PSMA)-targeting agent for preoperative molecular imaging and fluorescence-guided surgery for prostate cancer. J Labelled Comp Radiopharm. 2021;64:4–13.CrossRef Kim MH, Kim SG, Kim DW. Dual-labeled prostate-specific membrane antigen (PSMA)-targeting agent for preoperative molecular imaging and fluorescence-guided surgery for prostate cancer. J Labelled Comp Radiopharm. 2021;64:4–13.CrossRef
25.
Zurück zum Zitat Lee BS, Chu SY, Jung WJ, Jeong HJ, Lee K, Kim MH, et al. 18F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer. Prostate. 2020;80:1383–93.CrossRef Lee BS, Chu SY, Jung WJ, Jeong HJ, Lee K, Kim MH, et al. 18F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer. Prostate. 2020;80:1383–93.CrossRef
26.
Zurück zum Zitat Lee I, Lim I, Byun BH, Kim BI, Choi CW, Woo SK, et al. A microdose clinical trial to evaluate [18F] Florastamin as a positron emission tomography imaging agent in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:95–102.CrossRef Lee I, Lim I, Byun BH, Kim BI, Choi CW, Woo SK, et al. A microdose clinical trial to evaluate [18F] Florastamin as a positron emission tomography imaging agent in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:95–102.CrossRef
27.
Zurück zum Zitat Chang YS, Jeong JM, Kim BK, Cho JH, Lee DS, Chung JK, et al. Effect of carrier on labeling and biodistribution of Re-188-hydroxyethylidene diphosphonate. Nucl Med Mol Imaging. 2000;34:344–52. Chang YS, Jeong JM, Kim BK, Cho JH, Lee DS, Chung JK, et al. Effect of carrier on labeling and biodistribution of Re-188-hydroxyethylidene diphosphonate. Nucl Med Mol Imaging. 2000;34:344–52.
28.
Zurück zum Zitat Jeong JM, Lee YJ, Kim YJ, Chang YS, Lee DS, Chung JK, et al. Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid. Appl Radiat Isot. 2000;52:851–5.CrossRef Jeong JM, Lee YJ, Kim YJ, Chang YS, Lee DS, Chung JK, et al. Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid. Appl Radiat Isot. 2000;52:851–5.CrossRef
29.
Zurück zum Zitat Lee JD, Park KK, Lee M-G, Kim E-H, Rhim KJ, Lee JT, et al. Radionuclide therapy of skin cancers and Bowen’s disease using a specially designed skin patch. J Nucl Med. 1997;38:697–702.PubMed Lee JD, Park KK, Lee M-G, Kim E-H, Rhim KJ, Lee JT, et al. Radionuclide therapy of skin cancers and Bowen’s disease using a specially designed skin patch. J Nucl Med. 1997;38:697–702.PubMed
30.
Zurück zum Zitat Kim W, Jeong MH, Park OY, Rhew JY, Bom HS, Choi SJ, et al. Effects of beta-radiation using a holmium-166 coated balloon on neointimal hyperplasia in a porcine coronary stent restenosis model. Circ J. 2003;67:625–9.CrossRef Kim W, Jeong MH, Park OY, Rhew JY, Bom HS, Choi SJ, et al. Effects of beta-radiation using a holmium-166 coated balloon on neointimal hyperplasia in a porcine coronary stent restenosis model. Circ J. 2003;67:625–9.CrossRef
31.
Zurück zum Zitat Kim W, Jeong MH, Kim SH, Park WS, Park OY, Kim JH, et al. A novel method of brachytherapy using local delivery of 99mTc-HMPAO for coronary stent restenosis. Korean J Intern Med. 2004;19:179–88.CrossRef Kim W, Jeong MH, Kim SH, Park WS, Park OY, Kim JH, et al. A novel method of brachytherapy using local delivery of 99mTc-HMPAO for coronary stent restenosis. Korean J Intern Med. 2004;19:179–88.CrossRef
32.
Zurück zum Zitat Won JH, Lee JD, Wang HJ, Kim G-E, Kim BW, Yim H, et al. Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002;53:1005–13.CrossRef Won JH, Lee JD, Wang HJ, Kim G-E, Kim BW, Yim H, et al. Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002;53:1005–13.CrossRef
33.
Zurück zum Zitat Won JH, Lee JD, Wang HJ, Han JH, Kim JH, Kim KH, et al. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vasc Interv Radiol. 2005;16:705–11.CrossRef Won JH, Lee JD, Wang HJ, Han JH, Kim JH, Kim KH, et al. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vasc Interv Radiol. 2005;16:705–11.CrossRef
34.
Zurück zum Zitat Shin JH, Song HY, Moon DH, Oh SJ, Kim JS, Kim EH, et al. Effects of irradiation using a radioisotope-filled balloon on tissue hyperplasia caused by stent placement in a canine urethral model. Acta Radiol. 2006;47:436–43.CrossRef Shin JH, Song HY, Moon DH, Oh SJ, Kim JS, Kim EH, et al. Effects of irradiation using a radioisotope-filled balloon on tissue hyperplasia caused by stent placement in a canine urethral model. Acta Radiol. 2006;47:436–43.CrossRef
35.
Zurück zum Zitat Kim G, Chun K, Park SH, Kim B. Production of alpha-particle emitting 211At using 45 MeV alpha-beam. Phys Med Biol. 2014;59:2849–60.CrossRef Kim G, Chun K, Park SH, Kim B. Production of alpha-particle emitting 211At using 45 MeV alpha-beam. Phys Med Biol. 2014;59:2849–60.CrossRef
36.
Zurück zum Zitat Lee T, Kim M, Lee W, Kim B, Lim I, Song K, et al. Performance evaluation of a Compton SPECT imager for determining the position and distribution of 225Ac in targeted alpha therapy: a Monte Carlo simulation based phantom study. Appl Radiat Isot. 2019;154:108893.CrossRef Lee T, Kim M, Lee W, Kim B, Lim I, Song K, et al. Performance evaluation of a Compton SPECT imager for determining the position and distribution of 225Ac in targeted alpha therapy: a Monte Carlo simulation based phantom study. Appl Radiat Isot. 2019;154:108893.CrossRef
37.
Zurück zum Zitat Lee DJ, Han CY, Park SH, Kim JK. An accelerator-based epithermal neutron beam design for BNCT and dosimetric evaluation using a voxel head phantom. Radiat Prot Dosimetry. 2004;110:655–60.CrossRef Lee DJ, Han CY, Park SH, Kim JK. An accelerator-based epithermal neutron beam design for BNCT and dosimetric evaluation using a voxel head phantom. Radiat Prot Dosimetry. 2004;110:655–60.CrossRef
38.
Zurück zum Zitat Kim EH, Rhee CH. A microdosimetric approach to the thermal neutron fluence prescription for clinical BNCT. Radiat Prot Dosimetry. 2004;112:377–83.CrossRef Kim EH, Rhee CH. A microdosimetric approach to the thermal neutron fluence prescription for clinical BNCT. Radiat Prot Dosimetry. 2004;112:377–83.CrossRef
39.
Zurück zum Zitat Kim KO, Kim JK, Kim SY. Optimized therapeutic neutron beam for accelerator-based BNCT by analyzing the neutron angular distribution from 7Li(p, n)7Be reaction. Appl Radiat Isot. 2009;67:1173–9.CrossRef Kim KO, Kim JK, Kim SY. Optimized therapeutic neutron beam for accelerator-based BNCT by analyzing the neutron angular distribution from 7Li(p, n)7Be reaction. Appl Radiat Isot. 2009;67:1173–9.CrossRef
40.
Zurück zum Zitat Lee E, Lee CW, Cho G. Radiation safety analysis for the A-BNCT facility in Korea. Appl Radiat Isot. 2018;142:92–103.CrossRef Lee E, Lee CW, Cho G. Radiation safety analysis for the A-BNCT facility in Korea. Appl Radiat Isot. 2018;142:92–103.CrossRef
41.
Zurück zum Zitat Lee W, Sarkar S, Ahn H, Kim JY, Lee YJ, Chang Y, et al. PEGylated liposome encapsulating nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT). Biochem Biophys Res Commun. 2020;522:669–75.CrossRef Lee W, Sarkar S, Ahn H, Kim JY, Lee YJ, Chang Y, et al. PEGylated liposome encapsulating nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT). Biochem Biophys Res Commun. 2020;522:669–75.CrossRef
42.
Zurück zum Zitat Yoo J, Do Y. Synthesis of stable platinum complexes containing carborane in a carrier group for potential BNCT agents. Dalton Trans. 2009;(25):4978–86. Yoo J, Do Y. Synthesis of stable platinum complexes containing carborane in a carrier group for potential BNCT agents. Dalton Trans. 2009;(25):4978–86.
43.
Zurück zum Zitat Jung JY, Lu B, Yoon DK, Hong KJ, Jang H, Liu C, et al. Therapy region monitoring based on PET using 478 keV single prompt gamma ray during BNCT: A Monte Carlo simulation study. Phys Med. 2016;32:562–7.CrossRef Jung JY, Lu B, Yoon DK, Hong KJ, Jang H, Liu C, et al. Therapy region monitoring based on PET using 478 keV single prompt gamma ray during BNCT: A Monte Carlo simulation study. Phys Med. 2016;32:562–7.CrossRef
44.
Zurück zum Zitat Yoon DK, Jung JY, Jo Hong K, Sil Lee K, Suk SuhT. GPU-based prompt gamma ray imaging from boron neutron capture therapy. Med Phys. 2015;42:165–9.CrossRef Yoon DK, Jung JY, Jo Hong K, Sil Lee K, Suk SuhT. GPU-based prompt gamma ray imaging from boron neutron capture therapy. Med Phys. 2015;42:165–9.CrossRef
Metadaten
Titel
KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future
verfasst von
Byung Hyun Byun
Myoung Hyoun Kim
Yeon-Hee Han
Hwan-Jeong Jeong
Publikationsdatum
23.08.2021
Verlag
Springer Singapore
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 5/2021
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-021-00703-9

Weitere Artikel der Ausgabe 5/2021

Nuclear Medicine and Molecular Imaging 5/2021 Zur Ausgabe